hVIVO plc (LON:HVO - Get Free Report) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 15.76 ($0.21) and traded as high as GBX 17 ($0.23). hVIVO shares last traded at GBX 16.61 ($0.22), with a volume of 1,644,675 shares trading hands.
Analysts Set New Price Targets
Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research report on Thursday, April 10th.
Read Our Latest Report on HVO
hVIVO Stock Down 2.4 %
The firm's fifty day simple moving average is GBX 15.79 and its 200-day simple moving average is GBX 19.74. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market cap of £131.89 million, a PE ratio of 7.69 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Buying and Selling at hVIVO
In other news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($693,646.66). Company insiders own 14.03% of the company's stock.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
